Antibióticos orales versus inhalados para la bronquiectasia
Referencias
Referencias de los estudios excluidos de esta revisión
Ir a:
Aksamit TR, De Soyza A, Operschall E, Bandel T‐J, Krahn U, Montegriffo E, et al. Baseline demographic profile of subjects of the phase 3 RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non‐cystic fibrosis bronchiectasis (NCFB). American Thoracic Society 2016 International Conference 2016;193:A1768. [https://www.atsjournals.org/doi/abs/10.1164/ajrccm‐conference.2016.193.1_MeetingAbstracts.A1768]
NCT00749866. Long term nebulised gentamicin in patients with bronchiectasis [Can long term nebulised gentamicin reduce the bacterial burden, break the vicious cycle of inflammation and improve quality of life in patients with bronchiectasis]. clinicaltrials.gov/ct2/show/NCT00749866 (first received 9 September 2008).
NCT01313624. A study to see if AZLI (an inhaled antibiotic) is effective in treating adults with non‐cf bronchiectasis ‐ AIR‐BX1 [A phase 3, double‐blind, multicenter, randomized, placebo‐controlled trial evaluating repeated courses of aztreonam for inhalation solution in subjects with non‐cf bronchiectasis and gram‐negative endobronchial infection]. clinicaltrials.gov/ct2/show/NCT01313624 (first received 14 March 2011).
NCT01677403. A study to access safety and efficacy of nebulized tobramycin in patients with bronchiectasis [A randomized,controlled study to evaluate the efficacy,indications,adverse reactions and resistance of combined administration of nebulized tobramycin compared with systemic administration alone in patients with bronchiectasis]. clinicaltrials.gov/ct2/show/NCT01677403 (first received 3 September 2012).
O'Donnell AE, Bilton D, Serisier D, Wanner A, Froehlich J, Bruinenberg P, et al. ORBIT‐3 and ORBIT‐4: design of a phase 3 program to investigate safety and efficacy of pulmaquin in non‐cystic fibrosis bronchiectasis (NCFBE) patients chronically colonized with pseudomonas aeruginosa (PA). American Journal of Respiratory and Critical Care Medicine 2016;193:A1775.
Terpstra L, Altenburg J, Duijkers R, Boersma WG. Study design: effects of long term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non‐cystic fibrosis bronchiectasis a double blind, randomized, placebo and TIS twice daily (open label) controlled trial. The BATTLE study. American Journal of Respiratory and Critical Care Medicine 2016;193:A1788.
Referencias adicionales
Ir a:
Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al. Clinical phenotypes in adult patients with bronchiectasis. European Respiratory Journal 2016;47(4):1113‐22. [DOI: 10.1183/13993003.01899‐2015]
Aliberti S, Masefield S, Polverino E, De Soyza A, Loebinger MR, Menendez R, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. European Respiratory Journal 2016;48(3):632‐47. [DOI: 10.1183/13993003.01888‐2015]
Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics ‐ part 1: biological mechanisms. Respiration 2011;81(1):67‐74.
Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics ‐ part 2: advantages and disadvantages of long‐term, low‐dose macrolide therapy. Respiration 2011b;81(1):75‐87.
Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. Journal of the American Medical Association 2013;309(12):1251‐9.
Joint Formulary Committee. British National Formulary. www.medicinescomplete.com/mc/?utm_source=bnforg&utm_medium=homepage&utm_campaign=medicinescomplete (accessed 13 October 2016).
Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non‐cystic fibrosis bronchiectasis: a systematic review. European Respiratory Journal 2014;44(2):382‐93. [DOI: 10.1183/09031936.00018414]
Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. European Respiratory Journal 2015;45(5):1446‐62. [DOI: 10.1183/09031936.00119114]
Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. European Respiratory Journal 2016;2(1):00081‐2015. [DOI: 10.1183/23120541.00081‐2015]
Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012;186(7):657‐65.
Chang AB, Grimwood K, Mulholland K, Torzillo P. Bronchiectasis in Indigenous children in remote Australian communities. Medical Journal of Australia 2002;177:200‐4. [PUBMED: 12175325]
Chang AB, Bell SC, Byrnes CA, Grimwood K, HolmesP, King PT, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand: a position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation. Medical Journal of Australia 2010;193(6):356‐65.
Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis. Third Edition. London: Cystic Fibrosis Trust, 2009.
Donovan T, Felix LM, Chalmers JD, Milan SJ, Mathioudakis AG, Spencer S. Continuous versus intermittent antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews 2017, Issue 7. [DOI: 10.1002/14651858.CD012733]
Dudley MN, Loutit J, Griffith DC. Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Current Opinion in Biotechnology 2008;19(6):637‐43.
Gibson GJ, Loddenkemper R, Lundback Bo, Sibille Y (eds). Bronchiectasis. European Lung White Book: Respiratory Health and Disease in Europe. European Respiratory Society, 2013. [http://www.erswhitebook.org/]
Felix Lambert M, Grundy S, Milan Stephen J, Armstrong R, Harrison H, Lynes D, et al. Dual antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD012514]
Flume PA, O’Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey‐Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine 2007;176(10):957–69. [DOI: 10.1164/rccm.200705‐664OC]
Geller DE. Aerosol antibiotics in cystic fibrosis. Respiratory Care 2009;54(5):658‐70.
Goeminne P, Dupont L. Non‐cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgraduate Medical Journal 2010;86(1018):493‐501.
Goeminne PC, Vandooren J, Moelants EA, Decraene A, Rabaey E, Pauwels A, et al. The sputum colour chart as a predictor of lung inflammation, proteolysis and damage in non‐cystic fibrosis bronchiectasis: a case‐control analysis. Respirology 2014;19(2):203‐10.
Pieter G, De Soyza A. Bronchiectasis: how to be an orphan with many parents?. European Respiratory Journal 2016;47(1):10‐3.
McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 1 March 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Habesoglu MA, Ugurlu AO, Eyuboglu FO. Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Annals of Thoracic Medicine 2011;6(3):131‐6.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. European Respiratory Journal 2017;49(6):pii: 1700051. [DOI: 10.1183/13993003.00051‐2017]
Hnin K, Nguyen C, Carson KV, Evans DJ, Greenstone M, Smith BJ. Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD001392.pub3]
Kaehne A, Milan SJ, Felix LM, Spencer S, Sheridan E, Marsden PA. Head‐to‐head trials of antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews 2017, Issue 3. [DOI: 10.1002/14651858.CD012590]
Kelly C, Evans David J, Chalmers James D, Crossingham I, Spencer S, Relph N, et al. Macrolide antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD012406]
Kolbe J, Wells AU. Bronchiectasis: a neglected cause of respiratory morbidity and mortality. Respirology 1996;1(4):221‐5.
Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non‐cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Annals of the American Thoracic Society 2015;12(12):1764‐70.
Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]
Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non‐CF Guideline Group. British Thoracic Society guideline for non‐CF bronchiectasis. Thorax 2010;65 Suppl 1:i1‐58.
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal 2017;50(3):pii: 1700629. [10.1183/13993003.00629‐2017]
Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population‐based cohort study. European Respiratory Journal 2016;47(1):186‐93.
Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Annals of the American Thoracic Society 2014;11(3):425‐34.
Restrepo MI, Keyt H, Reyes LF. Aerolized antibiotics. Respiratory Care 2015;60(6):762‐1; discussion 771‐3.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respiratory Medicine 2010;104:981‐5.
Rubin BK. Aerosolized antibiotics for noncystic fibrosis bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2008;21(1):71‐6.
Ryan G, Singh M, Dwan K. Inhaled antibiotics for long‐term therapy in cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD001021.pub2]
Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis‐associated hospitalizations in the United States, 1993‐2006. Chest 2010;138:944‐9.
Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots DR. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000‐2007. Chest 2012;142(2):432‐9.
Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomised controlled trial. JAMA 2013;309(12):1260‐7.
Singleton R, Morris A, Redding G, Poll J, Holck P, Martinez P, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatric Pulmonology 2000;29(3):182‐7. [DOI: 10.1002/(SICI)1099‐0496(200003)29:3<182::AID‐PPUL5>3.0.CO;2‐T]
Southern KW, Barker PM, Solis‐Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD002203.pub4]
Welsh EJ, Evans DJ, Fowler SJ, Spencer S. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD010337.pub2]
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine 2005;12(4):205‐9.
Wilson R, Aksamit T, Aliberti S, De Soyza A, Elborn JS, Goeminne P, et al. Challenges in managing pseudomonas aeruginosa in non‐cystic fibrosis bronchiectasis. Respiratory Medicine 20165;117:179‐89.
Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet 2012;380(9842):660‐7.
Yang JW, Fan LC, Lu HW, Miao XY, Mao B, Xu JF. Efficacy and safety of long‐term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta‐analysis. Clinical Respiratory Journal2016; Vol. 10, issue 6:731‐9. [DOI: 10.1111/crj.12278]
Characteristics of studies
Characteristics of excluded studies [ordered by study ID]
| Study | Reason for exclusion |
| Wrong comparator. The trial compares inhaled ciprofloxacin to placebo. | |
| Wrong comparator. The trial compares inhaled ciprofloxacin to placebo. | |
| Wrong comparator. The trial compares inhaled gentamicin to placebo. | |
| Wrong intervention. The trial compares the addition of inhaled tobramycin to ciprofloxacin versus ciprofloxacin alone. | |
| Not a randomised controlled trial. The study sought to investigate the impact of long‐ and short‐term antibiotic treatment on inflammation. | |
| Wrong comparator. The trial compares inhaled tobramycin to placebo. | |
| Wrong comparator. The trial compares inhaled aztreonam to placebo. | |
| Wrong comparator. The trial compares inhaled ciprofloxacin to placebo. | |
| Wrong comparator. The trial compared inhaled and nebulised gentamicin to intravenous gentamicin in a triple cross‐over design. | |
| Letter to editor regarding "n of 1" trial of inhaled taurolidine versus placebo | |
| Wrong comparator. The trial compares inhaled gentamicin to placebo. | |
| Wrong comparator. The trial compares inhaled gentamicin to placebo. | |
| Wrong comparator. The trial compares inhaled aztreonam to placebo. | |
| Wrong comparator. The trial compares inhaled tobramycin to placebo. | |
| Wrong comparator. The trial compares inhaled tobramycin to placebo. | |
| Wrong comparator. The trial compares inhaled ciprofloxacin to placebo. | |
| Wrong comparator. The trial compares inhaled ceftazidime and tobramycin to usual care. | |
| Wrong comparator. The trial compares addition of inhaled antibiotics to intravenous antibiotics versus intravenous antibiotics alone. | |
| Letter to editor regarding trial of inhaled gentamicin compares to placebo | |
| Wrong intervention. The trial compares the addition of inhaled tobramycin to ciprofloxacin to ciprofloxacin alone. | |
| Wrong comparator. The trial compares inhaled ciprofloxacin to placebo. | |
| Wrong comparator. The trial compares inhaled colistin to usual care. | |
| Wrong comparator. The trial compares two different doses of inhaled tobramycin to placebo. | |
| Wrong comparator. The trial compares inhaled gentamicin to placebo. | |
| Wrong comparator. The trial compares inhaled gentamicin to placebo. | |
| Wrong comparator. The trial compares inhaled ciprofloxacin to placebo. | |
| Wrong intervention and wrong comparator. Trial compares intravenous followed by oral antibiotics for an acute exacerbation of bronchiectasis, versus a full intravenous course of antibiotics. |
Figuras y tablas -
Figure 1
Study flow diagram
